"We have another way to target this tumor resistance. We identified two separate targets that we can then target with enhanced EGFR inhibitor therapy."
"More than half of glioblastoma tumors have EGFR amplification. EGFR is commonly amplified in extrachromosomal DNAs that drive oncogene amplification and dysregulated gene expression."
"HELDR exhibits widespread genomic DNA binding: HELDR binds to promoters, gene bodies and intergenic regions to regulate global gene expression without affecting EGFR signaling."
A novel long non-coding RNA, named HELDR, has been discovered to drive glioblastoma cell growth alongside EGFR amplification. This finding may lead to new therapeutic strategies that enhance treatment sensitivity in glioblastoma. The study utilized RNA sequencing to identify HELDR's role in EGFR-amplified glioblastoma cell lines. HELDR binds to various genomic regions to regulate gene expression without impacting EGFR signaling. Glioblastoma remains a highly aggressive brain tumor with a low five-year survival rate, highlighting the need for effective treatment strategies.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]